Mesothelioma Doctors in New York

When a patient receives a mesothelioma diagnosis in New York, the next decision, choosing the right specialist, may be the single most consequential medical choice they make. New York State is home to several of the world's most respected cancer centers, and its concentration of thoracic oncologists, surgical specialists, and mesothelioma researchers gives patients access to care that simply isn't available in most parts of the country. According to the National Cancer Institute (NCI), mesothelioma is a rare and aggressive malignancy caused almost exclusively by asbestos exposure, and its complexity demands physicians with deep, specific experience in the disease.

New York's industrial history, particularly in shipbuilding along the Brooklyn Navy Yard, construction across Manhattan, and manufacturing in Buffalo and Albany, created decades of occupational asbestos exposure. The state has consistently ranked among the highest in the U.S. for mesothelioma incidence, according to the Centers for Disease Control and Prevention's 2022 mesothelioma surveillance report. That history has, in turn, driven investment in specialized oncology programs at institutions like Memorial Sloan Kettering Cancer Center (MSKCC), NewYork-Presbyterian Hospital, Mount Sinai Health System, and NYU Langone's Perlmutter Cancer Center.

Choosing a mesothelioma specialist isn't just about geography. It's about finding a physician who treats mesothelioma patients regularly, has access to a multidisciplinary team, and can connect you with clinical trials that may extend survival beyond the median. As Dr. Harvey Pass, Director of Thoracic Oncology at NYU Langone Health and one of the country's most published mesothelioma researchers, has stated publicly: "The volume of mesothelioma cases a surgeon sees directly correlates with outcomes. This is not a cancer where a generalist approach is sufficient."

This entry outlines New York's leading mesothelioma specialists and institutions, explains what to look for when selecting a doctor, and describes the types of treatment programs available across the state.

Mesothelioma care in New York is delivered by several distinct types of specialists, and most patients will work with more than one throughout their treatment. Understanding who does what helps you ask better questions and build a stronger care team.

Thoracic Oncologists

Thoracic oncologists specialize in cancers of the chest cavity, including the lungs, pleura, and mediastinum. For patients with pleural mesothelioma, the most common form of the disease, a thoracic oncologist is typically the lead physician. At Memorial Sloan Kettering, the Thoracic Oncology Service includes dedicated mesothelioma specialists who participate in national research consortiums and run active clinical trials.

Thoracic Surgeons

Surgery remains a primary treatment option for eligible patients, and New York's thoracic surgeons are among the most experienced in the country with procedures like extrapleural pneumonectomy (EPP) and pleurectomy/decortication (P/D). The choice between these two operations is one of the most debated questions in mesothelioma surgery, and having a surgeon who performs them frequently, not occasionally, matters enormously for outcomes.

Medical Oncologists

Medical oncologists manage systemic treatments including chemotherapy, immunotherapy, and targeted therapy. For mesothelioma patients, this often means overseeing regimens like cisplatin plus pemetrexed, which remains the standard first-line chemotherapy approved by the FDA, or newer immunotherapy combinations such as nivolumab plus ipilimumab, which received FDA approval in October 2020 for unresectable pleural mesothelioma.

Radiation Oncologists

Radiation plays a supporting role in mesothelioma treatment, often used after surgery or for palliative symptom control. New York institutions offer intensity-modulated radiation therapy (IMRT) and other advanced techniques that minimize damage to surrounding tissue.

Imagine you've just been told by a community pulmonologist that a pleural effusion on your chest X-ray looks suspicious. What happens next, and who you see next, will shape everything. In New York, patients with suspected mesothelioma have access to diagnostic pathways that combine advanced imaging, minimally invasive biopsy techniques, and specialized pathology review, all under one roof at major cancer centers.

Why Specialized Diagnosis Matters

Mesothelioma is notoriously difficult to diagnose correctly. According to a 2019 study published in Archives of Pathology and Laboratory Medicine, mesothelioma is misdiagnosed as other conditions, including adenocarcinoma or reactive mesothelial hyperplasia, in a meaningful percentage of cases when reviewed by non-specialist pathologists. Major New York centers employ dedicated thoracic pathologists who review tissue samples specifically for mesothelioma markers, using immunohistochemistry panels that include calretinin, WT-1, and D2-40 staining.

Diagnostic Tools Available in New York

Leading New York institutions offer the full spectrum of mesothelioma diagnostic tools. These include CT-guided core needle biopsy, video-assisted thoracoscopic surgery (VATS) for pleural biopsy, PET-CT scanning for staging, and next-generation genomic sequencing to identify mutations like BAP1 loss, which is present in a significant subset of mesotheliomas and has implications for prognosis and treatment selection. Mount Sinai's Tisch Cancer Institute has been particularly active in BAP1 research, given its history of studying asbestos-exposed populations in New York.

Seeking a Second Opinion

If your initial diagnosis came from a community hospital, getting a second opinion from an MSKCC or NYU Langone pathologist is strongly advisable. According to the NCI, second opinions on rare cancer pathology change the diagnosis or treatment recommendation in a clinically meaningful number of cases. Most New York specialists welcome second-opinion consultations and can review outside slides and imaging within days.

New York's major cancer centers treat mesothelioma with multimodal approaches, meaning they combine surgery, chemotherapy, radiation, and increasingly, immunotherapy, rather than relying on any single modality. The specific combination depends on the histological subtype of your tumor (epithelioid, sarcomatoid, or biphasic), the stage of disease, your overall health, and your treatment goals.

Memorial Sloan Kettering Cancer Center

MSKCC, located on the Upper East Side of Manhattan, is consistently ranked among the top cancer hospitals in the United States by U.S. News and World Report. Its mesothelioma program is part of the Thoracic Oncology Service and includes surgical, medical, and radiation oncologists who meet regularly as a multidisciplinary tumor board to review individual cases. MSKCC has been a principal site for major mesothelioma clinical trials, including studies evaluating CAR-T cell therapy targeting mesothelin, a protein highly expressed on mesothelioma cells.

NYU Langone's Perlmutter Cancer Center

Dr. Harvey Pass at NYU Langone is one of the most cited mesothelioma researchers in the world, with publications spanning surgical technique, biomarker discovery, and immunotherapy. The Perlmutter Cancer Center offers both EPP and P/D procedures and maintains an active biobank of mesothelioma tissue samples that supports ongoing translational research. NYU Langone has also been involved in studies evaluating blood-based biomarkers like fibulin-3 and soluble mesothelin-related peptides (SMRP) for earlier detection.

Mount Sinai Health System

Mount Sinai's connection to mesothelioma research runs deep. The Selikoff Centers for Occupational and Environmental Medicine at Mount Sinai, named for Dr. Irving Selikoff, the physician who first definitively linked asbestos to mesothelioma in a landmark 1964 study presented to the New York Academy of Sciences, continue to monitor and treat New York workers with asbestos-related diseases. The Tisch Cancer Institute provides comprehensive mesothelioma treatment and participates in NCI-sponsored cooperative group trials.

NewYork-Presbyterian Hospital

NewYork-Presbyterian, affiliated with both Columbia University Irving Medical Center and Weill Cornell Medicine, provides mesothelioma care through its thoracic surgery and oncology programs. The hospital's size and academic affiliation mean patients can access emerging treatments and subspecialty consultations that smaller centers can't offer.

Clinical Trials in New York

Access to clinical trials is one of the strongest arguments for seeking care at a major New York institution. According to ClinicalTrials.gov, as of 2024, MSKCC and NYU Langone together host more than a dozen active mesothelioma trials, including studies of novel immunotherapy combinations, targeted agents, and intraoperative treatments like hyperthermic intrathoracic chemotherapy (HITHOC). For patients whose disease has progressed on standard therapy, a clinical trial may represent the best available option.

Prognosis for mesothelioma remains challenging regardless of where you're treated, but the data consistently shows that treatment at high-volume, specialized centers is associated with better outcomes. According to a 2021 analysis published in The Annals of Thoracic Surgery, patients who underwent mesothelioma surgery at centers performing more than 10 resections per year had significantly lower perioperative mortality and longer median survival than those treated at low-volume institutions.

The median overall survival for pleural mesothelioma ranges from approximately 12 to 21 months depending on histology, stage, and treatment received, according to NCI data. Epithelioid mesothelioma, the most common subtype, carries the most favorable prognosis, while sarcomatoid tumors are more aggressive and respond poorly to most therapies. Patients with early-stage, epithelioid disease who are surgical candidates and receive multimodal therapy at centers like MSKCC or NYU Langone have achieved median survivals exceeding 2 years in published case series, with some long-term survivors reaching 5 years or beyond.

Immunotherapy has meaningfully shifted the prognosis conversation. The CheckMate 743 trial, published in The Lancet in 2021, demonstrated that nivolumab plus ipilimumab improved overall survival compared to chemotherapy in patients with unresectable pleural mesothelioma, with a 2-year survival rate of 41% in the immunotherapy arm versus 27% in the chemotherapy arm. New York institutions were among the enrolling sites for this landmark trial.

Living with a mesothelioma diagnosis in New York means navigating not just medical decisions but also logistical, financial, and emotional ones. New York's major cancer centers recognize this and offer wraparound support services that extend well beyond the clinic.

Patient Navigation and Support Services

MSKCC, NYU Langone, and Mount Sinai all offer dedicated patient navigators who help coordinate appointments across specialties, assist with insurance authorization, and connect patients with social workers and palliative care teams. Palliative care at these institutions is integrated into treatment planning from the time of diagnosis, not reserved for end-of-life situations. According to a 2010 study in the New England Journal of Medicine, early palliative care integration improved both quality of life and survival in patients with advanced lung cancer, a finding that has shaped how leading cancer centers approach mesothelioma care.

Financial and Legal Resources

Mesothelioma treatment is expensive, and many New York patients have legal recourse given the occupational origins of their asbestos exposure. New York is home to numerous mesothelioma attorneys who work on contingency and have experience with both asbestos trust fund claims and personal injury litigation. The Mesothelioma Applied Research Foundation (MARF) also provides financial assistance resources and connects patients with peer support programs. Your care team's social worker can help identify financial assistance programs, including those offered by pharmaceutical manufacturers for patients receiving costly immunotherapy agents.

Caregiver Support

Family members and caregivers often feel as overwhelmed as patients. Programs at MSKCC and NYU Langone include caregiver support groups, counseling services, and educational workshops specifically designed for families navigating a mesothelioma diagnosis. You don't have to manage this alone, and your care team's social work department is a good first call if you're not sure where to start.